NCT07476729
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 6 more changesShow less
- Start date changed from estimate of Apr 1, 2026 to Sep 1, 2026
- Eligibility criteria expanded, about 37 words
- Study sites: 20 to 21
- Secondary endpoints: details revised at 2 of 16 entries
- Publications: details revised at 18 of 18 entries
- Study description expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (16)
Show 11 moreShow less
Arms and interventions
prospective, randomized 1:1, open label phase II/III trial comparing arm AI (ALLR3-MITOX) versus arm BI (InO). Randomization is stratified according to frontline treatment group (BFM, AIEOP, ALLTogether, other) and localization of relapse (BM+CNS, other)
single arm trial with 3 courses of blinatumomab, the 1st replacing the consolidation chemotherapy element SCB2, the 2nd added on after the consolidation chemotherapy element SCB3, and the 3rd added on after the consolidation element SCB4 and 8 weeks of conventional maintenance therapy, then followed by conventional maintenance therapy being applied without reinduction chemotherapy pulses until week 132, as compared to historical controls (IntReALL BCP 2020 SR SOC induction arm compared with IntReALL SR 2010 arm B without epratuzumab)
single arm trial with HC1 and 1 course of blinatumomab followed by allo-HSCT compared with historical controls
single arm trial with the IntReALL SR 2010 Arm A (ALL-REZ BFM 2002) including blinatumomab replacing the chemotherapy element SCA3 compared with historical controls. SR patients will receive further conventional consolidation, local irradiation and maintenance, HR patients will be given allo-HSCT after blinatumomab
Drugs: Inotuzumab ozogamicin (INO), Blinatumomab
Sites
21 sites in 21 countries
Austria 1, Belgium 1, Czechia 1, Denmark 1, Finland 1, France 1, Germany 1, Hungary 1, Israel 1, Italy 1, Netherlands 1, Norway 1, Poland 1, Portugal 1, Romania 1, Slovakia 1, Slovenia 1, Spain 1, Sweden 1, Switzerland 1, Turkey (Türkiye) 1